ReviewReviews in medical virology2017
Vaccines against Middle East respiratory syndrome coronavirus for humans and camels.
Review in Reviews in medical virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Recent Advances in Camel Immunology.Frontiers in immunology · 2020Pooled it
- Review
- Mucosal immunity in upper and lower respiratory tract to MERS-CoV.Frontiers in immunology · 2024Review
- Virus-like particle vaccinology, from bench to bedside.Cellular & molecular immunology · 2022Review
- Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.The Lancet. Microbe · 2022Article
- Neutralization of MERS coronavirus through a scalable nanoparticle vaccine.NPJ vaccines · 2021Article
- Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate.Veterinary sciences · 2021Article
- Potential zoonotic sources of SARS-CoV-2 infections.Transboundary and emerging diseases · 2021Review
- One Health in the context of coronavirus outbreaks: A systematic literature review.One health (Amsterdam, Netherlands) · 2020Review
- Challenge infection model for MERS-CoV based on naturally infected camels.Virology journal · 2020Article
- Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels.Scientific reports · 2019Article
- Article
- Aerobic bacteriological studies on the respiratory tracts of apparently healthy and pneumonic camels (Camelus dromedaries) in selected districts of Afar Region, Ethiopia.Tropical animal health and production · 2018Article
- A Mini Review of the Zoonotic Threat Potential of Influenza Viruses, Coronaviruses, Adenoviruses, and Enteroviruses.Frontiers in public health · 2018Review
- An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus.Viruses · 2017Review
- Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism.Scientific reports · 2017Article
- Article
- Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus.One health (Amsterdam, Netherlands) · 2017Review
- Vaccines against Middle East respiratory syndrome coronavirus for humans and camels.Reviews in medical virology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is caused by a novel betacoronavirus that was isolated in late 2012 in Saudi Arabia. The viral infections have been reported in more than 1700 humans, ranging from asymptomatic or mild cases to severe pneumonia with a mortality rate of 40%. It is well documented now that dromedary camels contract the infection and shed the virus without notable symptoms, and such animals had been infected by at least the early 1980s. The mechanism of camel to human transmission is still not clear, but several primary cases have been associated with camel contact. There is no approved antiviral drug or vaccine against MERS-CoV despite the active research in this area. Vaccine candidates have been developed using various platforms and regimens and have been tested in several animal models. Here, this article reviews the published studies on MERS-CoV vaccines with more focus on vaccines tested in large animals, including camels. It is foreseeable that the 1-health approach could be the best way of tackling the MERS-CoV endemic in the Arabian Peninsula, by using the mass vaccination of camels in the affected areas to block camel to human transmission. Camel vaccines can be developed in a faster time with fewer regulations and lower costs and could clear this virus from the Arabian Peninsula if accompanied by efficient public health measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.